Article

May 12, 2006

Medtronic: For your approval

This is a sample of how your ads will appear around selected BPHcontent. Your ads will be the exclusive content on BPH articles andwill rotate with the other sponsors on General News items.

If you can, please provide up to 150 words to include about your company.

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!

Related Content

July 24th 2025

Aquablation procedures for prostate cancer completed at ambulatory surgery center

Hannah Clarke

The WATER IV PCa trial is comparing first-line Aquablation therapy with radical prostatectomy for the treatment of patients with localized prostate cancer.

July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

July 23rd 2025

FDA clears image-guided navigation platform for focal therapy in prostate cancer

Hannah Clarke

The new advanced annotation workflow on the UroNav System is designed to work in tandem with DynaCAD Urology to support focal therapy planning.

June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD

Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.

July 23rd 2025

When to report 50320 with 49187 for nephrectomy procedures

Jonathan Rubenstein, MD Mark Painter

"As always, we encourage you to communicate among all team members and pay attention to your documentation," write Jonathan Rubenstein, MD, and Mark Painter.

Published: July 22nd 2025 | Updated: July 23rd 2025

Irreversible electroporation with NanoKnife found safe, effective for prostate tissue ablation

Hannah Clarke

The PRESERVE trial met its primary end point by demonstrating a negative in-field biopsy rate of 71% at 12 months.

Related Content

July 24th 2025

Aquablation procedures for prostate cancer completed at ambulatory surgery center

Hannah Clarke

The WATER IV PCa trial is comparing first-line Aquablation therapy with radical prostatectomy for the treatment of patients with localized prostate cancer.

July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

July 23rd 2025

FDA clears image-guided navigation platform for focal therapy in prostate cancer

Hannah Clarke

The new advanced annotation workflow on the UroNav System is designed to work in tandem with DynaCAD Urology to support focal therapy planning.

June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD

Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.

July 23rd 2025

When to report 50320 with 49187 for nephrectomy procedures

Jonathan Rubenstein, MD Mark Painter

"As always, we encourage you to communicate among all team members and pay attention to your documentation," write Jonathan Rubenstein, MD, and Mark Painter.

Published: July 22nd 2025 | Updated: July 23rd 2025

Irreversible electroporation with NanoKnife found safe, effective for prostate tissue ablation

Hannah Clarke

The PRESERVE trial met its primary end point by demonstrating a negative in-field biopsy rate of 71% at 12 months.

Medtronic: For your approval

Newsletter